Please wait while we gather the requested information from the database...

Get Involved
| Contact Us | Join SOT | Site Map | Help
Submit Button for the Search Form
Login: Email address
Submit Button for the Login Form
Forgot your Password?

Meet The Leaders

2015–2016 Council

Peter L. Goering

Sliver Spring, Maryland

Experience: Dr. Goering is currently a Research Toxicologist and Lab Leader, Laboratory of Toxicology and Biocompatibility, at the US FDA, Center for Devices and Radiological Health, in Silver Spring, Maryland. He earned his PhD from the University of Kansas Medical Center, and did a postdoctoral fellowship at the NIEHS focusing on the toxicology of metals and metal defense mechanisms. At the US FDA, his research interests include nanotoxicology, evaluating liver and kidney toxic injury, elucidating new biomarkers of toxicity, and understanding mechanisms of metal toxicity. Dr. Goering has co-authored over 80 peer-reviewed publications and book chapters, is a Diplomate of the American Board of Toxicology in 1994, and was named a Fellow of Academy of Toxicological Sciences in 2006. He serves as an adjunct professor in the Toxicology Program at the University of Maryland and The George Washington University’s Department of Biological Sciences. He has been active professionally in the Society of Toxicology (SOT) in several capacities. He is a member of the National Capital Area Chapter (NCAC-SOT) Regional Chapter, and served as its President in 2000–2001. He served as a Councilor (1992–1994) and President (1999–2000) of the SOT Metals Specialty Section; SOT Nominating Committee member (2004–2006); and Regulatory Affairs and Legislative Assistance Committee member (2003–2006), Chairperson from 2004–2006.

John B. Morris
Vice President

University of Connecticut

Experience: Dr. Morris is a Board of Trustees Distinguished Professor at the University of Connecticut. He has been on the faculty of the Toxicology Program for 32 years and served as the director of the program from 2000–2010. He served as the head of the Pharmaceutical Sciences Department (2002–2010), assistant dean for research (2008–2013) and is currently completing his term as interim dean of the School of Pharmacy at the University. He maintains active research interests in inhalation toxicology and quantitative inhalation risk assessment and has authored approximately 90 papers and book chapters in the field. His research publications have received many awards including Faculty of 1000 recognition for being among the top 2% of publications in biomedical literature for his work on the counter-irritant effects of menthol in cigarette smoke. He served on the editorial boards of Fundamental and Applied Toxicology, Toxicological Sciences, and Inhalation Toxicology and on the TOX-2 and ALTOX-4 Study Sections for NIH. He has served on air pollutant health assessment review panels for the states of Connecticut, Vermont, and Virginia, as well as for the US Environmental Protection Agency, Centers for Disease Control Agency for Toxic Substances and Disease Registry, and the Department of Energy Office of Health and Environmental Research. He currently serves on two National Academy of Sciences panels. He is a Fellow of the Academy of Toxicological Sciences.

Patricia E. Ganey
Vice President-Elect

Michigan State University

Experience: Experience: Dr. Ganey is professor of Pharmacology and Toxicology at Michigan State University. She is active in training medical and graduate students and in research. Her research focuses on understanding mechanisms by which inflammation modulates sensitivity of the liver to toxic agents and on understanding mechanisms of drug-induced liver injury. She has authored over 120 research publications in the area of toxicology, and her work has been recognized by the Faculty of 1,000. She has served on the editorial board for Toxicological Sciences and is currently on the editorial boards for Toxicology, the Journal of Toxicology and Environmental Health, and the Journal of Pharmacology and Experimental Therapeutics. She has reviewed grant applications for NIH and served as a consultant for the National Toxicology Program Office of the Report on Carcinogens. In addition to her service to SOT, Dr. Ganey has represented the interests of Toxicology by serving in the presidential chain for the Division of Toxicology of the American Society for Pharmacology and Experimental Therapeutics.

Leigh Ann Burns Naas

Gilead Sciences, Inc

Experience: Dr. Burns Naas is Vice President of Drug Safety Evaluation at Gilead Sciences, Inc. She was a Therapeutic Area Leader for Infectious Disease, Vaccines, and Oncology at Pfizer in Drug Safety research and Development over the 10 years preceding her move to Gilead. Prior to that, she worked as a product toxicologist in Health, Environmental, and regulatory Affairs at Dow Corning Corporation in Midland, Michigan. Throughout her career, her work has focused on strategic aspects and the design of safety programs to support chemical product development and registration, and to support the clinical development and licensure for small molecules and biotherapeutics, including vaccines. Dr. Burns Naas has been active in both the Society of Toxicology (SOT) and the American College of Toxicology (ACT) serving on several committees both elected and appointed in both, and serves on the Editorial Board for two journals. She has demonstrated a long commitment to promoting advancements in basic and applied toxicology, the impact of science on human and environmental health across multiple scientific organizations and in the literature, and to participating in the training/education of the next generation of toxicologists. Dr. Burns Naas received her doctorate degree in pharmacology and toxicology from the Medical College of Virginia/VCU in 1992 with an emphasis on immunotoxicology.

Ruth A. Roberts


Experience: Dr. Roberts is senior director at AstraZeneca and is adjunct professor at the University of Birmingham, United Kingdom. She was President of EUROTOX (2012–2014), a past board member and current fellow of the Academy of Toxicological Sciences (ATS), Past President and Life Fellow of the British Toxicology Society (FBTS), a EUROTOX-Registered Toxicologist (ERT), a fellow of the Society of Biology (FSB) and a fellow of the Royal College of Pathologists (FRCPath). She chaired the 2011 Gordon Conference ‘Cellular and Molecular Mechanisms of Toxicity’ and is also current chair of the ILSI HESI Emerging Issues Committee. She has more than 20 years experience working in the forefront of international research and regulatory toxicology across pharmaceutical, agrochemical, and industrial chemical fields. Dr. Roberts is widely recognized for her expertise in cancer biology, apoptosis, preclinical strategies, and drug development. With more than 130 publications in peer-reviewed journals, Dr. Roberts received the SOT achievement award in 2002 and the EUROTOX Bo Holmstedt Award in 2008 for outstanding scientific contributions to drug and chemical safety.

George P. Daston

Procter & Gamble Company

Experience: Dr. Daston is a toxicologist at Procter & Gamble, 1985–present, and is a Victor Mills Society Research Fellow; assistant professor, biology, University of Wisconsin- Milwaukee, 1983–1985; NRC Postdoctoral Fellow, US EPA (RTP), 1981–1983; adjunct professor, developmental biology and pediatrics, University of Cincinnati and Children’s Hospital Research Foundation, since 1989; President, Teratology Society, 1999–2000; Editor-in-Chief, Birth Defects Research Part B: Developmental and Reproductive Toxicology, since 2003.

Norbert E. Kaminski
Past President

Michigan State University

Experience: Dr. Kaminski is a professor of pharmacology and toxicology and director of the Center for Integrative Toxicology at Michigan State University. He holds joint appointments in the College of Human Medicine and Veterinary Medicine at Michigan State University. Dr. Kaminski joined the Michigan State faculty in 1993. Dr. Kaminski held the rank of assistant professor at the Medical College of Virginia in the Department of Pharmacology and Toxicology from 1998–1999. He received his doctorate degree in toxicology and physiology from North Carolina State University in 1985 and his master’s degree from North Carolina State University in toxicology in 1981. He is a founding member of the Editorial Board for Nonlinearity in Biology, Toxicology and Medicine, and is currently on the editorial board for the journals Toxicology and Journal of Immunotoxicology. Dr. Kaminski served as a member of Council as well as Chair of the Membership Committee for the Society on NeuroImmune Pharmacology. He also serves on the Board of Trustee for the International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) and currently serves as treasurer. He has been a member of various advisory panels including the National Academy of Sciences and the US EPA Science Advisory Board and has also served on numerous peer review panels.

Aaron Barchowsky

University of Pittsburgh

Experience: Dr. Barchowsky has extensive faculty experience in pharmacology, toxicology, and environmental and occupational health. He trained numerous graduate students and fellows, lectured in pharmacology and toxicology, directed core courses in medical pharmacology and in environmental health, and served on numerous graduate program committees. As director of the Environmental Health Sciences MS/PhD program in the University of Pittsburgh Graduate School of Public Health, he is active in student recruitment, curriculum development, and mentoring. After beginning his career in safety pharmacology of cardiovascular drugs, he has led a constantly active research program investigating the molecular pathogenesis of diseases caused by environmental exposures to metals. His laboratory has produced seminal work in arsenic toxicology including work recognized by the SOT 2005 Best Paper in Toxicological Sciences Award. In addition, his expertise in arsenic toxicology has been recognized through nomination and service on a number of national and international policy committees including the US EPA SAB Arsenic Committee (2005–2010), NRC Arsenic Committee (2013–2015), and WHO FERG global burden of disease committee (2011–present). He served on numerous scientific review committees for toxicology-related funding applications and is currently a standing member of the Xenobiotic and Nutrient Disposition and Action study section. He has been an associate editor of Toxicological Sciences since 2007 with special focus on metals, signal transduction, and cardiovascular toxicology.

Rosonald R. Bell

Pfizer Inc., Worldwide Research and Development

Experience: Dr. Bell received his BS in biology/premedicine from Florida Agriculture and Mechanical University in Tallahassee, Florida in 1981 and his MS and PhD in pharmaceutical sciences with a concentration in pharmacology/toxicology from Florida Agriculture and Mechanical University in 1989 and 1992, respectively. In 1992, Dr. Bell accepted a two-year postdoctoral research position with The Upjohn Company (now Pfizer Inc.) in Kalamazoo, Michigan under the direction of Dr. Gerald J. Kolaja, where he was involved in nephrotoxicity method development and gained a familiarity with nonclinical drug safety assessment. In 1994, following his postdoctoral fellowship, Dr. Bell joined Ciba Pharmaceuticals Corporation (now Novartis Pharmaceuticals Corporation) in Summit, New Jersey as study director and also managed both the general and reproductive toxicology groups. He became certified in general toxicology in 1996, as a diplomate of the American Board of Toxicology. In 1998, Dr. Bell joined GD Searle/Monsanto in Skokie, Illinois and his primary role was as a Discovery and Development Project Team representative on projects in the arthritis and inflammation therapeutic area. In 2003, Dr. Bell accepted an associate research fellow position with Pfizer Inc. Dr. Bell currently serves as both a regulatory strategy lead and a drug safety team lead at Pfizer Inc., Groton, Connecticut, with the primary responsibility for Pre-FIH—LOE oversight of submissions and regulatory strategies. His responsibilities also include the design and implementation of research projects to support nonclinical safety evaluation of therapeutic agents with special emphasis on injectable anti-inflammatory biotherapeutics. His research interest is in heavy induced pulmonary toxicity with an emphasis on uncovering the biochemical and cytological alterations.

Myrtle A. Davis

Bethesda, Maryland

Experience: Dr. Davis is the currently the Branch Chief for Toxicology and Pharmacology in the Developmental Therapeutics Program of the Division of Cancer Diagnostics and Treatment of the National Cancer Institute and serves as Scientific Director of the Laboratory of Investigative Toxicology at the Frederick National Laboratory for Cancer Research (FNLCR). Her responsibilities include serving as the Toxicology expert for project and program teams in drug discovery through first human dose, providing mechanistic toxicology expertise to teams, creating and leading major research initiatives within DTP and managing the daily operations of the Toxicology and Pharmacology Branch. Prior to her appointment at NCI, she held the position of Research Advisor in the Investigative Toxicology Group at Lilly Research Labs, Eli Lilly and company. Prior to taking the position at Eli Lilly, Dr. Davis was an Associate Professor in the Department of Pathology at the University of Maryland, School of Medicine where she had an active research program exploring mechanisms of toxicant-induced apoptosis and the role of protein phosphorylation. She has served the society throughout the years by serving on the Communications Committee 2011-2012, the Regulatory Affairs and Legislative Assistance Committee, 2005–2006; The Scientific Program Committee 2008–2011, and as President of the Comparative and Veterinary Specialty Section (Vice President Elect 2003–2004, Vice President 2004–2005, President 2005–2006, Past President 2006–2007). She was also a member, Institute for Laboratory Animal Research Council, The National Academies of Sciences for a six-year term ending in 2012. She served as Co-Editor in Chief for the ILAR Journal and has served and an Associate Editor for various Toxicology journals including Toxicological Sciences. She served as a member of the standing NIH Study Section ALTX1 for five years. She has authored several book chapters and co authored peer-reviewed publications on a range of topics including apoptosis, toxicant induced cell signaling and biomarkers of injury.

Ofelia A. Olivero


Experience: Dr. Olivero was trained as a cytogeneticist in Argentina, and then did postdoctoral training at NIH in the National Cancer Institute. Her career continued in that organization, where she held positions of visiting associate, staff scientist, and senior staff scientist. She was able to combine her expertise in genetic toxicology with carcinogenesis. Her seminal observations on the transplacental carcinogenesis of agents used in AIDS therapy generated the field of molecular epidemiology of nucleoside analogs. She is presently applying molecular cytogenetic techniques to understand nucleoside analog induced carcinogenesis in an attempt to provide knowledge to generate safer drugs and treatments for HIV-1 patients. Dr. Olivero has generated a change in the culture of mentoring through her recent book on interdisciplinary mentoring and by delivering multiple talks and workshops on the topic. She is recognized nationally and internationally for her scientific profile and her mentoring knowledge. Additionally, she has shown a singular style of leadership based on consensus and inclusion and is currently president of the Environmental Mutagenesis and Genomics Society (formerly EMS), has been president of the Genetic Toxicology Association, and holds numerous positions in many scientific organizations. Her natural leadership, talent, and mentoring abilities together with her scientific creativity have empowered numerous young individuals to pursue careers in toxicology.

Tao Wang

Novartis Pharmaceuticals Corporation

Experience: Experience: Dr. Wang brings a diverse professional experience to SOT, from an oncology clinical practice to investigating gene regulation in the academic setting, as well as working as a toxicologist in the CRO and pharmaceutical industries. She has been with Novartis Pharmaceuticals for more than a decade, and is currently an associate director in the Preclinical Safety Department. Dr. Wang leads safety assessment for oncology and non-oncology drug development projects, and provides overall expert opinion regarding risk assessment in support of clinical trials. During her tenure at Novartis, Dr. Wang received multiple awards, recognizing not only her significant achievements and performance above and beyond work requirements (e.g. Novartis Above & Beyond, Due Diligence, and Catalyst Awards), but also her outstanding collaboration on multidisciplinary teams (e.g., Novartis Team Award). In addition, Dr. Wang participates in teaching a Practical Toxicology course at the University of California at Berkeley as a guest lecturer. She is a member of the Board of Directors for the American Board of Toxicology (ABT) and chairs the ABT Globalization Committee. She also serves on the editorial board for the International Journal of Toxicology.

John A. Wisler

San Diego, California

Experience: Dr. Wisler is currently Director of Toxicology at Dart Neuroscience. He has more than 25 years of experience in scientific toxicology leadership roles including management of toxicology facilities; PhD level toxicologists; consumer product risk assessment; and nonclinical drug development ranging from discovery safety evaluations through post marketing regulatory activities for both large and small molecule modalities. He earned his doctorate degree in toxicology from Indiana University (School of Medicine) in 1988 subsequently served as a National Research Council postdoctoral fellow with the US Army Institute of Chemical Defense. He then held nonclinical leadership roles as an Associate Director with a CRO (IRDC/ MPI); Senior Toxicologist with the Procter & Gamble Company; Toxicology Director with Allergan; and Scientific Director in Toxicology Sciences at Amgen. He has held leadership positions in SOT Regional Chapters and Specialty Sections; served on the American Board of Toxicology (ABT) board of directors; and is a Past President of ABT.

Clarissa L. Russell
Executive Director

Experience: Ms. Russell Wilson has been Deputy Director for the Society of Toxicology since 1996. In addition, she has been Senior Vice President, Association Innovation and Management (AIM), an association management company providing administrative services to the toxicology community, since the inception of the company in 1999. Ms. Russell Wilson has earned a Master in Business Administration with a concentration in finance from Johns Hopkins University. Along with earning her undergraduate degree from James Madison University and she also earned a culinary degree from the École hôtelière de Lausanne in conjunction with the University of Nevada, Las Vegas.

Share this page.

SOT —Dedicated to Creating a Safer and Healthier World by Advancing the Science of Toxicology.

© 2015 Society of Toxicology. All rights reserved.

Privacy Policy and Disclaimer | Contact Us